PARP1 and cancer: In fact, PARP inhibitors have been widely used in clinic as monotherapeutic agents to block single-strand DNA (ssDNA) repair thereby inducing the synthetic lethality in cancers including ovarian, breast, and pancreatic cancer (Jiang et al., 2019; Slade, 2020; Zhu et al., 2020).